Critical Outcome T Com Npv (COTQF) Stock Rating Upgraded by Zacks Investment Research
According to Zacks, “Critical Outcome Technologies Inc. is a biopharmaceutical company which focuses on treatment of cancer. The company’s product consists of COTI-2, a novel p53-dependent mechanism of action with selective and potent anti-cancer activity. Its artificial intelligence platform, CHEMSAS, utilizes a series of predictive computer models to identify compounds from disease specific drug discovery through chemical optimization and preclinical testing. Critical Outcome Technologies Inc. is based in London, Canada. “
Shares of Critical Outcome T Com Npv (NASDAQ:COTQF) opened at 0.384 on Monday. Critical Outcome T Com Npv has a 52 week low of $0.16 and a 52 week high of $0.69. The firm’s market capitalization is $57.11 million. The company has a 50-day moving average of $0.25 and a 200 day moving average of $0.22.
COPYRIGHT VIOLATION WARNING: This news story was first reported by The Cerbat Gem and is the propert of of The Cerbat Gem. If you are accessing this news story on another domain, it was copied illegally and republished in violation of international copyright and trademark laws. The correct version of this news story can be read at https://www.thecerbatgem.com/2016/11/30/critical-outcome-t-com-npv-cotqf-stock-rating-upgraded-by-zacks-investment-research.html.
Receive News & Stock Ratings for Critical Outcome T Com Npv Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Critical Outcome T Com Npv and related stocks with our FREE daily email newsletter.